Furthermore, immature forms of CTSs could be released from AML cells, transported via EVs and then activated in the tumor environment, thus modulating pro-tumor mechanisms such as drug resistance and inflammation [50]. The gene discussed is CTSS; the disease is acute myeloid leukemia.